Rapport Therapeutics (RAPP)

• Market cap: $1.29B
• 1 day: -1.38%
• 5 days: -3.04%
• 1 month: -9.01%
• 3 months: -15.11%
• 6 months: 3.72%
• Year to date: -3.66%
• 1 year: 167.59%
• 5 years: 30.19%
• 10 years: 30.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Employees: 69